CCR2 and neoplasm: Research has demonstrated that blocking the CCL2/CCR2 axis with CCR2 antagonists, either on their own or in conjunction with other compounds, reduces the presence of MDSC in tumors and enhances tumor condition in preclinical mouse models (Nywening et al. 2016).